XBIX ETF — Corgi U.S. Biotech 2x Daily ETF

Corgi U.S. Biotech 2x Daily ETF (XBIX)

Updated October 16, 2026.

XBIX is an ETF. its expense ratio is 0.45%. Total return is 14.9% over the past 0.4 years, 13.2 points ahead of SPY at 1.7%.

Corgi U.S. Biotech 2x Daily ETF is a leveraged equity ETF that seeks to deliver twice the daily performance of U.S. biotechnology companies through derivatives such as swaps and futures, with an expense ratio of 0.45%. The fund does not maintain a regular distribution schedule. This ETF is designed for tactical traders and experienced investors seeking amplified exposure to biotech sector movements on a daily basis, though the leverage structure means losses are also magnified and the fund may experience significant decay over longer holding periods.

XBIX performance versus SPY

Price and return data through 2026-10-16.

Total return is 14.9% over the past 0.4 years, 13.2 points ahead of SPY at 1.7%.

XBIX key facts

Issuer

Corgi Strategies

Asset type

ETF

Asset class

Equity

Inception date

06/03/2026

Expense ratio

0.45%

Distribution frequency

None

Last close

$29.66 (as of 2026-10-16)

AUM

$1,012,760

Average volume

2423.0

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: Corgi Strategies; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

Who may consider XBIX — and who may not

It is a weaker fit for investors who need monthly cash flow (XBIX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on XBIX

• All tickers starting with X

Tagged: Leverage, Healthcare.

Frequently asked questions

More securities from Corgi Strategies.